Breaking News

You are here » Indian-Commodity  :  Corporate  :  Central Bank of India reports net loss of Rs 2,113.51 crore in Q4

18-May2018

Central Bank of India reports net loss of Rs 2,113.51 crore in Q4

Central Bank of India has reported results for the fourth quarter and year ended March 31, 2018. 

The Bank has reported a net loss of Rs 2,113.51 crore for the quarter ended March 31, 2018 as compared net loss of Rs 591.77 crore for the same quarter in the previous year. Total income of the Bank decreased by 11.51% at Rs 6,301.50 crore for quarter under review as compared to Rs 7,121.05 crore for the quarter ended March 31, 2017.

For the year ended March 31, 2018, the Bank has posted a net loss at Rs 5,104.91 crore as compared to net loss of Rs 2,439.10 crore for the previous year. Total income of Bank decreased by 3.19% at Rs 26,657.86 crore for year under review as compared to Rs 27,537.05 crore for the year ended March 31, 2017.


Related News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......